Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock Short Interest Report for October

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 47,382 shares, a growth of 200.8% from the October 15th total of 15,751 shares. Based on an average daily trading volume, of 1,264,801 shares, the short-interest ratio is presently 0.0 days. Approximately 2.7% of the shares of the stock are sold short.

Insider Activity

In other Bolt Biotherapeutics news, major shareholder Coastlands Capital Lp acquired 50,000 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were purchased at an average cost of $6.38 per share, with a total value of $319,000.00. Following the purchase, the insider owned 462,416 shares in the company, valued at approximately $2,950,214.08. The trade was a 12.12% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO William Quinn sold 9,132 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $3.24, for a total transaction of $29,587.68. Following the completion of the sale, the chief executive officer directly owned 25,384 shares in the company, valued at approximately $82,244.16. The trade was a 26.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 38,584 shares of company stock worth $128,361 over the last quarter. Insiders own 9.40% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd bought a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics makes up about 0.0% of Nan Fung Group Holdings Ltd’s investment portfolio, making the stock its 25th largest position. Nan Fung Group Holdings Ltd owned about 0.26% of Bolt Biotherapeutics at the end of the most recent reporting period. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Performance

Bolt Biotherapeutics stock opened at $5.91 on Friday. Bolt Biotherapeutics has a fifty-two week low of $3.10 and a fifty-two week high of $7.78. The company has a market capitalization of $11.38 million, a price-to-earnings ratio of -0.36 and a beta of 0.85. The stock has a fifty day moving average of $4.58 and a two-hundred day moving average of $4.52. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($2.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.68) by $1.43. The business had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.45 million. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. On average, analysts anticipate that Bolt Biotherapeutics will post -11.10 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $14.50.

Check Out Our Latest Stock Analysis on Bolt Biotherapeutics

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.

Featured Stories

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.